RxDoctor Payments Data

Kriezel Charmel Presta, PA

Physician Assistant · North Haven, CTNPI 1316316474

Payments from drug & device makers

$1,795in general payments, 2019–2025

Across 149 payments — averaging $12.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$801
  • AbbVie$207
  • Viiv Healthcare Company$161
  • Bayer$119
  • Lilly USA, LLC$116
  • Takeda Pharmaceuticals U.S.A., Inc.$94
  • plus $297 from 7 others

What the payments were for

  • Food & beverage$1,795100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,795 in reported general payments places this provider in the 85th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$26,555
Medicare patients
77
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$36,878
OzempicSemaglutide23$26,954
Tresiba Flextouch U-200Insulin Degludec23$25,865
Repatha SureclickEvolocumab23$23,363
RybelsusSemaglutide12$22,799
TrulicityDulaglutide11$18,519
TrintellixVortioxetine Hydrobromide23$17,241
MounjaroTirzepatide14$14,871
EliquisApixaban15$13,596
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,931
LinzessLinaclotide16$12,919
VascepaIcosapent Ethyl11$4,610
Levothyroxine Sodium84$2,327
Ondansetron Hcl15$2,170
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$801$49,75335 claims
Lilly USA, LLCTrulicity, Mounjaro$116$33,39025 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$94$17,24123 claims
AbbVieLinzess, Synthroid$207$14,62840 claims
GSKTrelegy Ellipta$85$12,93120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in North Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →